Pfizer stock holds near USD 28 as new products gain ground

Published on 09/23/2026 at 11:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pfizer stock closed at USD 27.93 on September 22, 2026, up 12.2 percent year to date. New products reached USD 3.2 billion in Q2 2026 sales.

Fotorealistische unbeschriftete Pharma-Anlage bei Dämmerung, Symbolbild für Pfizer Inc — Fotorealistische Pharma-Produktionsanlage bei Dämmerung symbolisiert Pfizer Inc. mit ISIN US7170811035 im Biotech-Sektor, Illustration mit AI erstellt.

Pfizer Inc. (US7170811035) closed at USD 27.93 on the NYSE on September 22, 2026, leaving the shares 12.2 percent higher year to date and close to the 52-week high of USD 29.21. The current investor debate centers on whether new medicines can offset the continuing decline in COVID-related revenue.

New products reach USD 3.2 billion

According to MarketBeat on September 22, 2026, Pfizer generated USD 3.2 billion from new, acquired and launched products in the second quarter of 2026, up 18 percent from the same quarter a year earlier. That followed 22 percent growth in the first quarter of 2026, giving the portfolio shift a measurable operating footprint.

The latest quarterly report also showed earnings per share of USD 0.77 and revenue of USD 15.03 billion in the quarter ended June 2026, according to MarketBeat. EPS exceeded the cited consensus estimate of USD 0.68 by USD 0.09, while revenue surpassed the USD 14.40 billion estimate by USD 0.63 billion.

COVID revenue remains the counter-factor

The same MarketBeat report said COVID products generated about USD 11 billion in 2024 and approximately USD 6.7 billion in 2025, while Pfizer guided for USD 4 billion in 2026. The numerical decline makes the replacement task clear: new products must expand faster than the COVID franchise contracts.

Pfizer has set fiscal-year 2026 earnings guidance at USD 2.80 to USD 3.00 per share, according to MarketBeat. The range provides a benchmark for the November reporting cycle and is more concrete than a broad recovery narrative.

Stock stays below USD 29.21

On September 22, 2026, Pfizer stock traded between USD 27.49 and USD 28.00, with volume of 26.7 million shares and market capitalization of about USD 159 billion. The 52-week range of USD 23.58 to USD 29.21 places the closing price USD 1.28 below the high and USD 4.35 above the low.

Analyst expectations remain close to the market price. MarketBeat reported an average target of USD 28.39 and a consensus Hold rating, while HSBC raised its target from USD 28.00 to USD 30.00 on September 10, 2026, also retaining a Hold rating.

Pfizer stock closes at USD 27.93

Pfizer stock closed at USD 27.93 on the NYSE on September 22, 2026. The company had a market capitalization of about USD 159 billion on the latest cited market snapshot, while the next major valuation test is the earnings update scheduled for November 3, 2026, according to Yahoo Finance.